Granulocyte-Macrophage-Colony-Stimulating Factor Support in Patients with Acute Non-Lymphatic Leukemia

Oncology (Switzerland)

Volumn 53, Issue 6, 1996, Pages 482-487

  Nel, J S ^a   Falkson, Carta I ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Acute non lymphoblastic leukemia; Cytarabine; Duration of neutropenia; Etoposide; GM CSF; Mitoxantrone

Indexed keywords

ALLOPURINOL; COTRIMOXAZOLE; CYTARABINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE PAIN; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONVULSION; DEPRESSION; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN CELL; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MALE; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; SUDDEN DEATH; SURVIVAL TIME; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CYTARABINE; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFANT; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; NEUTROPENIA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029999545     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227624     Document Type: Article

References (20)

1. Link H, Freund M, Dicdrich H, Wilke H, Au-stcin J, Henke M, Wandl H, Fackler-Schwalbe E, Schlimok G, Hoffman R: Miloxantrone, cytosine arabinoside and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia, Hematol Bluttransfus 1990:33:322-325.
2. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstcin W: Combination of mitoxantrone and ctoposide in refractory acute myelogenous leukemia - an active and well tolerated regimen, J Clin Oncol 1988;6:213-217.
3. Arlin Z, Case DC Jr., Moore J, Wiernik P, Feldman E, Salctan S, Dcsai P, Sia L, Cartwright K: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphocytic leukemia (ANLL), Lcdcrle Cooperative Group, Leukemia 1990:4:177-183.
4. Groopman JE, Molina JM, Scaddcn DT: Hemopoietic growth factors, Biology and clinical implications, N Engl J Med 1989:321:1449-1459.
5. Griffin J, Lowcnberg B: Clonogenic cells in acute myeloblastic leukemia, Blood 1986:68: 1185-1195.
6. Begley C, Metcalf D, Nicola NA: Purified colony stimulating factors (G-CSF and GM-CSF) induce differentiation in human HL-60 leukemic cell lines with suppression of clonogenic-ity, Int J Cancer 1987;39:99-105.
7. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutz-ky J, Graham G: Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells, Leukemia 1988:2:810-813.
8. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M: Treatment with interleukin-3 plus granulocytic macrophage colony stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts, Blood 1991:78:2674-2679.
9. Chcsson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Strass S, Weinstein H, Woods WG: Report of the National Cancer Institute-Sponsored Workshop on Definitions of Diagnosis and Response in AML, J Clin Oncol 1990;8:813-819.
10. Oken MM, Creech RH, Tormey CD, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol 1982;5: 649-655.
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7), A report of the French-American-British Cooperative Group, Ann Intern Med 1985;103:460-462.
12. Dorr RT: Clinical properties of yeast-derived vs, Escherichia-coli-derived granulocyte-mac-rophagc colony-stimulating factor, Clin Ther 1993;15:19-29.
13. Rowe JM, Anderson JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmaucr EA, Wiernik PH: Phase II randomized placebo-controlled study of yeast derived GM-CSF in adult patients (55-70 years) with AML, Blood 1993:82:3299.
14. Stone P, George S, Berg D, Paciucci P, Schiffer C: GM-CSF vs, placebo during remission induction for patients>60 years old with de novo acute myeloid leukemia, Proc Am Soc Clin Oncol 1994:13:304.
15. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines, J Clin Oncol 1994; 12:2471-2508.
16. Bernstein SH: Growth factors in the management of adult acute leukemia [review], Hema-tol Oncol Clin North Am 1993;7:255-274.
17. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredic K, Bodcy GP, Kurzrock R, Tal-paz M, Freireich EJ, Deisseroth AB: Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony-stimulating factor, Blood 1990:75:1766-1769.
18. Buchner T, Hiddcmann W, Koenigsmann M, Zuhlsdorf M, Wormann B, Bocckmann A, Frcire EA, Innig G, Maschmcyer G, Ludwig WD: Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse, Blood 1991; 78:1190-1197.
19. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmaucr E, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (El490), Blood 1995;86:457-462.
20. Hiddeman W, Zuhlsdorf, M, Wormann B, Koenigsmann M, Buchner T: Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy - A care report on the basis of a clinical phase II trial, Leuk Res 1990;14:347-352.